262 related articles for article (PubMed ID: 11367526)
1. Structure/function of C5 convertases of complement.
Rawal N; Pangburn MK
Int Immunopharmacol; 2001 Mar; 1(3):415-22. PubMed ID: 11367526
[TBL] [Abstract][Full Text] [Related]
2. Formation of high-affinity C5 convertases of the alternative pathway of complement.
Rawal N; Pangburn M
J Immunol; 2001 Feb; 166(4):2635-42. PubMed ID: 11160326
[TBL] [Abstract][Full Text] [Related]
3. Formation of high affinity C5 convertase of the classical pathway of complement.
Rawal N; Pangburn MK
J Biol Chem; 2003 Oct; 278(40):38476-83. PubMed ID: 12878586
[TBL] [Abstract][Full Text] [Related]
4. Structure and function of complement C5 convertase enzymes.
Pangburn MK; Rawal N
Biochem Soc Trans; 2002 Nov; 30(Pt 6):1006-10. PubMed ID: 12440962
[TBL] [Abstract][Full Text] [Related]
5. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme.
Rawal N; Pangburn MK
J Biol Chem; 1998 Jul; 273(27):16828-35. PubMed ID: 9642242
[TBL] [Abstract][Full Text] [Related]
6. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
7. Activation of complement component C5: comparison of C5 convertases of the lectin pathway and the classical pathway of complement.
Rawal N; Rajagopalan R; Salvi VP
J Biol Chem; 2008 Mar; 283(12):7853-63. PubMed ID: 18204047
[TBL] [Abstract][Full Text] [Related]
8. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
Kinoshita T; Dodds AW; Law SK; Inoue K
Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
[TBL] [Abstract][Full Text] [Related]
9. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
[TBL] [Abstract][Full Text] [Related]
10. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.
Zwarthoff SA; Berends ETM; Mol S; Ruyken M; Aerts PC; Józsi M; de Haas CJC; Rooijakkers SHM; Gorham RD
Front Immunol; 2018; 9():1691. PubMed ID: 30083158
[TBL] [Abstract][Full Text] [Related]
11. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
12. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.
DiScipio RG
Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218
[TBL] [Abstract][Full Text] [Related]
13. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
Pangburn MK
J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
[TBL] [Abstract][Full Text] [Related]
14. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.
Laursen NS; Andersen KR; Braren I; Spillner E; Sottrup-Jensen L; Andersen GR
EMBO J; 2011 Feb; 30(3):606-16. PubMed ID: 21217642
[TBL] [Abstract][Full Text] [Related]
15. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.
Rooijakkers SH; Wu J; Ruyken M; van Domselaar R; Planken KL; Tzekou A; Ricklin D; Lambris JD; Janssen BJ; van Strijp JA; Gros P
Nat Immunol; 2009 Jul; 10(7):721-7. PubMed ID: 19503103
[TBL] [Abstract][Full Text] [Related]
17. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
18. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
[TBL] [Abstract][Full Text] [Related]
19. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b.
Kozono H; Kinoshita T; Kim YU; Takata-Kozono Y; Tsunasawa S; Sakiyama F; Takeda J; Hong K; Inoue K
J Biol Chem; 1990 Aug; 265(24):14444-9. PubMed ID: 2387864
[TBL] [Abstract][Full Text] [Related]
20. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
